Doubling Down: Merck Serono Inks Second Oncology Deal With Chinese Biotech BeiGene
This article was originally published in PharmAsia News
Executive Summary
German drug maker Merck Serono inked its second global licensing, co-development and commercialization deal this year with Chinese biotech BeiGene. During a signing ceremony in Beijing, execs from both companies talked about their development strategy.